Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04887194 · ClinicalTrials.gov registry record · Phase 1
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
A Phase 1 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04887194 is a Phase 1 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT04887194, a Phase 1 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Study 516-010 is an open-label Phase 1, drug-drug interaction and QTc study evaluating the effect of sitravatinib on probe substrates for CYP450 enzymes and BCRP and P-gp transporters.
Interventions
- DRUG Midazolam
- DRUG Digoxin
- DRUG Warfarin
- DRUG Dextromethorphan
- DRUG Sitravatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-04-08 |
| Est. Completion | 2022-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04887194
The ClinicalTrials.gov registry entry for NCT04887194 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT04887194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04887194 about?
NCT04887194 is a clinical study titled "PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates". Study 516-010 is an open-label Phase 1, drug-drug interaction and QTc study evaluating the effect of sitravatinib on probe substrates for CYP450 enzymes and BCRP and P-gp transporters.
What is the current status of trial NCT04887194?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2021-04-08. Estimated completion is 2022-12-22.
What interventions are being tested in trial NCT04887194?
The interventions under investigation include: Midazolam (DRUG), Digoxin (DRUG), Warfarin (DRUG), Dextromethorphan (DRUG), Sitravatinib (DRUG).
Who is sponsoring clinical trial NCT04887194?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.